Clinical Trial

CO2 Fractional Laser With Tranexamic Acid As An Effective Tool For Post Burn Hyperpigmentation.

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
It will be a case within control trial. After IRB approval patients presenting with more than 6 months old hyperpigmented burn scars will be included in this study. All data (including age, gender, mode of burn) will be recorded on a proforma and standardized pre-intervention photographs will be taken. The hyperpigmented scar will be divided into two equal halves.One half will receive fractional CO2 wit TXA solution other half will receive fractional CO2 Laser with N/S solution.Thus allocation will be done randomly with the lottery method. Total 3 sessions of LADD will be done with 1 month interval between each session. The following settings will be used: probe frequency 75Hz; Power range 12-15W; dwell time 300 micros-500 micros, stach 1-2 and spacing 900-1200m. The TXN solution will be prepared by mixing 250mg of TXA in 5ml of N/S creating a 5% TXN solution. Standardized photographs will again be taken 3 months after the 3rd session. The pre- and post-treatment photographs will be assessed by Skin Hyperpigmentation Index (SHI) using a smartphone dermatoscope adapter and an online calculator, freely available at: https://shi.skini magea nalys is.com, can be used. 15. Any complications during treatment will be noted and documented. Patient satisfaction wil be measured on a Likert scale of 1-5.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-19; most recent amendment 2026-04-05.
Trial Details
NCT Number NCT07195539
Lead Sponsor King Edward Medical University
Conditions Post Burn Hyperpigmentation
Enrollment 30 participants
Start Date 2025-06-01
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-07